# A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea

> **NCT05428345** · — · RECRUITING · sponsor: **Takeda** · enrollment: 600 (estimated)

## Conditions studied

- Ulcerative Colitis
- Crohn's Disease
- Inflammatory Bowel Disease (IBD)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05428345
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-25
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05428345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05428345, "A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05428345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*